Symbols / AMGN $348.05 -0.54%
AMGN Chart
About
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 187.62B |
| Enterprise Value | 234.94B | Income | 7.71B | Sales | 36.75B |
| Book/sh | 16.07 | Cash/sh | 16.93 | Dividend Yield | 288.00% |
| Payout | 66.90% | Employees | 31500 | IPO | — |
| P/E | 24.44 | Forward P/E | 14.95 | PEG | — |
| P/S | 5.11 | P/B | 21.66 | P/C | — |
| EV/EBITDA | 14.14 | EV/Sales | 6.39 | Quick Ratio | 0.73 |
| Current Ratio | 1.14 | Debt/Eq | 640.27 | LT Debt/Eq | — |
| EPS (ttm) | 14.24 | EPS next Y | 23.28 | EPS Growth | 112.10% |
| Revenue Growth | 8.60% | Earnings | 2026-04-30 | ROA | 7.93% |
| ROE | 106.10% | ROIC | — | Gross Margin | 70.78% |
| Oper. Margin | 30.55% | Profit Margin | 20.98% | Shs Outstand | 539.07M |
| Shs Float | 537.60M | Short Float | 2.81% | Short Ratio | 5.04 |
| Short Interest | — | 52W High | 391.29 | 52W Low | 261.43 |
| Beta | 0.42 | Avg Volume | 2.62M | Volume | 1.69M |
| Target Price | $350.03 | Recom | Buy | Prev Close | $349.92 |
| Price | $348.05 | Change | -0.54% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$350.03
Mean price target
2. Current target
$346.85
Latest analyst target
3. DCF / Fair value
$250.49
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$346.85
Low
$200.00
High
$432.00
Mean
$350.03
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-10 | init | Jefferies | — → Hold | $350 |
| 2026-02-20 | init | Barclays | — → Equal-Weight | $350 |
| 2026-02-19 | main | Wells Fargo | Equal-Weight → Equal-Weight | $375 |
| 2026-02-18 | main | Piper Sandler | Overweight → Overweight | $432 |
| 2026-02-06 | main | Argus Research | Buy → Buy | $400 |
| 2026-02-06 | main | Guggenheim | Neutral → Neutral | $347 |
| 2026-02-04 | main | Citigroup | Neutral → Neutral | $345 |
| 2026-02-04 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $309 |
| 2026-02-04 | main | Cantor Fitzgerald | Neutral → Neutral | $350 |
| 2026-02-04 | main | Leerink Partners | Outperform → Outperform | $355 |
| 2026-01-26 | main | UBS | Buy → Buy | $390 |
| 2026-01-20 | down | Bernstein | Outperform → Market Perform | $335 |
| 2026-01-08 | main | Truist Securities | Hold → Hold | $319 |
| 2025-12-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $304 |
| 2025-12-10 | main | Wells Fargo | Equal-Weight → Equal-Weight | $325 |
| 2025-12-03 | main | BMO Capital | Outperform → Outperform | $372 |
| 2025-11-27 | main | Leerink Partners | Outperform → Outperform | $305 |
| 2025-11-14 | main | Piper Sandler | Overweight → Overweight | $381 |
| 2025-11-06 | main | Cantor Fitzgerald | Neutral → Neutral | $315 |
| 2025-11-05 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $329 |
- Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance ue, 17 Mar 2026 21
- Rocatinlimab Halt Puts Spotlight On Amgen Pipeline Risks And Valuation - simplywall.st hu, 19 Mar 2026 22
- AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock? - Zacks Investment Research hu, 19 Mar 2026 15
- Here’s Why Amgen’s Free Cash Flow Could Nearly Double in 2026 - TIKR.com Mon, 16 Mar 2026 14
- AMGEN INC. (AMGN) - MSN Wed, 18 Mar 2026 15
- Amgen Inc. $AMGN Stock Position Lessened by Mizuho Markets Cayman LP - MarketBeat ue, 17 Mar 2026 11
- AMGN Shares Surpass 50 & 200-Day Moving Averages: What’s the Best Strategy? - Bitget hu, 19 Mar 2026 18
- AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND - PR Newswire Wed, 04 Mar 2026 21
- Amgen (AMGN) Valuation Check As Recent Share Momentum Cools - simplywall.st Wed, 18 Mar 2026 11
- Amgen Inc. $AMGN Shares Purchased by AIA Group Ltd - MarketBeat hu, 19 Mar 2026 07
- Is Trending Stock Amgen Inc. (AMGN) a Buy Now? - Yahoo Finance Mon, 16 Mar 2026 13
- GAMMA Investing LLC Raises Stock Position in Amgen Inc. $AMGN - MarketBeat hu, 19 Mar 2026 11
- National Bank of Canada FI Purchases 863,216 Shares of Amgen Inc. $AMGN - MarketBeat ue, 17 Mar 2026 11
- Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate - Yahoo Finance ue, 24 Feb 2026 08
- Stillwater Wealth Management Group Purchases New Shares in Amgen Inc. $AMGN - MarketBeat hu, 19 Mar 2026 09
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 119782 | 18727916 | — | Conversion of Exercise of derivative security at price 156.35 per share. | BRADWAY ROBERT A | Chief Executive Officer | — | 2026-03-04 00:00:00 | D |
| 1 | 10723 | — | — | Stock Award(Grant) at price 0.00 per share. | GRAHAM JONATHAN P | General Counsel | — | 2026-03-03 00:00:00 | D |
| 2 | 13403 | — | — | Stock Award(Grant) at price 0.00 per share. | GORDON MURDO | Officer | — | 2026-03-03 00:00:00 | D |
| 3 | 11259 | — | — | Stock Award(Grant) at price 0.00 per share. | SANTOS ESTEBAN | Officer | — | 2026-03-03 00:00:00 | D |
| 4 | 42657 | — | — | Stock Award(Grant) at price 0.00 per share. | BRADWAY ROBERT A | Chief Executive Officer | — | 2026-03-03 00:00:00 | D |
| 5 | 12063 | — | — | Stock Award(Grant) at price 0.00 per share. | GRIFFITH PETER H. | Chief Financial Officer | — | 2026-03-03 00:00:00 | D |
| 6 | 2010 | — | — | Stock Award(Grant) at price 0.00 per share. | GRYGIEL NANCY A | Officer | — | 2026-03-03 00:00:00 | D |
| 7 | 1876 | — | — | Stock Award(Grant) at price 0.00 per share. | KHOSLA RACHNA | Officer | — | 2026-03-03 00:00:00 | D |
| 8 | 3484 | — | — | Stock Award(Grant) at price 0.00 per share. | MILLER DEREK | Officer | — | 2026-03-03 00:00:00 | D |
| 9 | 938 | — | — | Stock Award(Grant) at price 0.00 per share. | BUSCH MATTHEW C. | Officer | — | 2026-03-03 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.14 | 0.11 | 0.14 | 0.11 |
| NormalizedEBITDA | 16.90B | 13.36B | 14.80B | 12.17B |
| TotalUnusualItems | 0.00 | 0.00 | -1.50B | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | -1.50B | |
| NetIncomeFromContinuingOperationNetMinorityInterest | 7.71B | 4.09B | 6.72B | 6.55B |
| ReconciledDepreciation | 5.17B | 5.59B | 4.07B | 3.42B |
| ReconciledCostOfRevenue | 12.04B | 12.86B | 8.45B | 6.41B |
| EBITDA | 16.90B | 13.36B | 14.80B | 12.17B |
| EBIT | 11.73B | 7.76B | 10.73B | 8.75B |
| NetInterestIncome | -2.75B | -3.15B | -2.88B | -1.41B |
| InterestExpense | 2.75B | 3.15B | 2.88B | 1.41B |
| NormalizedIncome | 7.71B | 4.09B | 6.72B | 6.55B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 7.71B | 4.09B | 6.72B | 6.55B |
| TotalExpenses | 27.67B | 26.17B | 20.29B | 16.76B |
| TotalOperatingIncomeAsReported | 9.08B | 7.26B | 7.90B | 9.57B |
| DilutedAverageShares | 542.00M | 541.00M | 538.00M | 541.00M |
| BasicAverageShares | 538.00M | 537.00M | 535.00M | 538.00M |
| DilutedEPS | 14.23 | 7.56 | 12.49 | 12.11 |
| BasicEPS | 14.33 | 7.62 | 12.56 | 12.18 |
| DilutedNIAvailtoComStockholders | 7.71B | 4.09B | 6.72B | 6.55B |
| NetIncomeCommonStockholders | 7.71B | 4.09B | 6.72B | 6.55B |
| NetIncome | 7.71B | 4.09B | 6.72B | 6.55B |
| NetIncomeIncludingNoncontrollingInterests | 7.71B | 4.09B | 6.72B | 6.55B |
| NetIncomeContinuousOperations | 7.71B | 4.09B | 6.72B | 6.55B |
| TaxProvision | 1.26B | 519.00M | 1.14B | 794.00M |
| PretaxIncome | 8.98B | 4.61B | 7.86B | 7.35B |
| OtherIncomeExpense | 2.65B | 506.00M | 2.83B | -814.00M |
| OtherNonOperatingIncomeExpenses | 2.65B | 506.00M | 2.83B | -814.00M |
| SpecialIncomeCharges | 0.00 | 0.00 | -1.50B | |
| OtherSpecialCharges | 1.50B | |||
| NetNonOperatingInterestIncomeExpense | -2.75B | -3.15B | -2.88B | -1.41B |
| InterestExpenseNonOperating | 2.75B | 3.15B | 2.88B | 1.41B |
| OperatingIncome | 9.08B | 7.26B | 7.90B | 9.57B |
| OperatingExpense | 15.63B | 13.31B | 11.84B | 10.35B |
| OtherOperatingExpenses | 1.31B | 248.00M | 879.00M | 503.00M |
| ResearchAndDevelopment | 7.27B | 5.96B | 4.78B | 4.43B |
| SellingGeneralAndAdministration | 7.05B | 7.10B | 6.18B | 5.41B |
| GrossProfit | 24.71B | 20.57B | 19.74B | 19.92B |
| CostOfRevenue | 12.04B | 12.86B | 8.45B | 6.41B |
| TotalRevenue | 36.75B | 33.42B | 28.19B | 26.32B |
| OperatingRevenue | 35.15B | 32.03B | 26.91B | 24.80B |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 538.80M | 537.00M | 535.40M | 534.00M |
| ShareIssued | 538.80M | 537.00M | 535.40M | 534.00M |
| NetDebt | 45.48B | 48.13B | 53.67B | 31.32B |
| TotalDebt | 54.60B | 60.10B | 64.61B | 38.95B |
| TangibleBookValue | -32.30B | -40.46B | -45.04B | -27.95B |
| InvestedCapital | 63.26B | 65.98B | 70.84B | 42.61B |
| WorkingCapital | 3.57B | 5.93B | 11.94B | 6.50B |
| NetTangibleAssets | -32.30B | -40.46B | -45.04B | -27.95B |
| CommonStockEquity | 8.66B | 5.88B | 6.23B | 3.66B |
| TotalCapitalization | 58.66B | 62.43B | 69.40B | 41.02B |
| TotalEquityGrossMinorityInterest | 8.66B | 5.88B | 6.23B | 3.66B |
| StockholdersEquity | 8.66B | 5.88B | 6.23B | 3.66B |
| GainsLossesNotAffectingRetainedEarnings | -258.00M | -66.00M | -289.00M | -231.00M |
| OtherEquityAdjustments | -56.00M | 308.00M | 9.00M | 117.00M |
| ForeignCurrencyTranslationAdjustments | -202.00M | -374.00M | -298.00M | -348.00M |
| UnrealizedGainLoss | 0.00 | 0.00 | 0.00 | |
| RetainedEarnings | -25.11B | -27.59B | -26.55B | -28.62B |
| CapitalStock | 34.02B | 33.53B | 33.07B | 32.51B |
| CommonStock | 34.02B | 33.53B | 33.07B | 32.51B |
| TotalLiabilitiesNetMinorityInterest | 81.93B | 85.96B | 90.92B | 61.46B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 56.44B | 62.86B | 72.53B | 45.77B |
| OtherNonCurrentLiabilities | 2.38B | 2.35B | 2.33B | 2.65B |
| TradeandOtherPayablesNonCurrent | 2.69B | 2.35B | 4.68B | 5.76B |
| NonCurrentDeferredLiabilities | 1.37B | 1.62B | 2.35B | 11.00M |
| NonCurrentDeferredTaxesLiabilities | 1.37B | 1.62B | 2.35B | 11.00M |
| LongTermDebtAndCapitalLeaseObligation | 50.01B | 56.55B | 63.17B | 37.35B |
| LongTermDebt | 50.01B | 56.55B | 63.17B | 37.35B |
| CurrentLiabilities | 25.49B | 23.10B | 18.39B | 15.69B |
| CurrentDebtAndCapitalLeaseObligation | 4.60B | 3.55B | 1.44B | 1.59B |
| CurrentDebt | 4.60B | 3.55B | 1.44B | 1.59B |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.44B | 1.33B | 1.38B | 1.10B |
| CurrentProvisions | 548.00M | 542.00M | ||
| PayablesAndAccruedExpenses | 19.45B | 18.22B | 15.57B | 13.00B |
| CurrentAccruedExpenses | 15.35B | 12.45B | 11.11B | 9.09B |
| InterestPayable | 867.00M | 936.00M | 470.00M | |
| Payables | 4.10B | 5.77B | 4.46B | 3.90B |
| DividendsPayable | 1.36B | 1.28B | 1.21B | 1.14B |
| TotalTaxPayable | 379.00M | 2.58B | 1.66B | 1.20B |
| IncomeTaxPayable | 379.00M | 2.58B | 1.66B | 1.20B |
| AccountsPayable | 2.37B | 1.91B | 1.59B | 1.57B |
| TotalAssets | 90.59B | 91.84B | 97.15B | 65.12B |
| TotalNonCurrentAssets | 61.53B | 62.81B | 66.82B | 42.94B |
| OtherNonCurrentAssets | 12.66B | 9.93B | 9.61B | 5.90B |
| GoodwillAndOtherIntangibleAssets | 40.96B | 46.34B | 51.27B | 31.61B |
| OtherIntangibleAssets | 22.28B | 27.70B | 32.64B | 16.08B |
| Goodwill | 18.68B | 18.64B | 18.63B | 15.53B |
| NetPPE | 7.91B | 6.54B | 5.94B | 5.43B |
| AccumulatedDepreciation | -11.12B | -10.39B | -9.81B | -9.28B |
| GrossPPE | 19.03B | 16.93B | 15.75B | 14.71B |
| ConstructionInProgress | 3.39B | 2.05B | 1.55B | 1.21B |
| OtherProperties | 5.22B | 5.00B | 4.81B | 4.68B |
| MachineryFurnitureEquipment | 5.14B | 4.73B | 4.54B | 4.32B |
| BuildingsAndImprovements | 4.93B | 4.80B | 4.51B | 4.20B |
| LandAndImprovements | 348.00M | 346.00M | 339.00M | 292.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 29.06B | 29.03B | 30.33B | 22.19B |
| OtherCurrentAssets | 1.19B | 1.14B | 281.00M | 355.00M |
| PrepaidAssets | 2.94B | 2.14B | 1.65B | 1.20B |
| Inventory | 6.22B | 7.00B | 9.52B | 4.93B |
| FinishedGoods | 1.89B | 2.06B | 2.78B | 1.00B |
| WorkInProcess | 3.42B | 4.12B | 5.75B | 3.10B |
| RawMaterials | 915.00M | 818.00M | 993.00M | 828.00M |
| Receivables | 9.57B | 6.78B | 7.94B | 6.39B |
| DuefromRelatedPartiesCurrent | 521.00M | 502.00M | 700.00M | 780.00M |
| TaxesReceivable | 198.00M | 172.00M | 129.00M | 164.00M |
| AccountsReceivable | 9.57B | 6.78B | 7.27B | 5.56B |
| CashCashEquivalentsAndShortTermInvestments | 9.13B | 11.97B | 10.94B | 9.30B |
| OtherShortTermInvestments | 0.00 | 1.68B | 48.00M | |
| CashAndCashEquivalents | 9.13B | 11.97B | 10.94B | 7.63B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 8.10B | 10.39B | 7.36B | 8.79B |
| RepurchaseOfCapitalStock | 0.00 | -200.00M | 0.00 | -6.36B |
| RepaymentOfDebt | -5.00B | -3.60B | -1.45B | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | 27.78B | 6.92B |
| CapitalExpenditure | -1.86B | -1.10B | -1.11B | -936.00M |
| EndCashPosition | 9.13B | 11.97B | 10.94B | 7.63B |
| BeginningCashPosition | 11.97B | 10.94B | 7.63B | 7.99B |
| ChangesInCash | -2.84B | 1.03B | 3.31B | -360.00M |
| FinancingCashFlow | -10.86B | -9.41B | 21.05B | -4.04B |
| CashFlowFromContinuingFinancingActivities | -10.86B | -9.41B | 21.05B | -4.04B |
| NetOtherFinancingCharges | -735.00M | -783.00M | -719.00M | -400.00M |
| CashDividendsPaid | -5.12B | -4.83B | -4.56B | -4.20B |
| CommonStockDividendPaid | -5.12B | -4.83B | -4.56B | -4.20B |
| NetCommonStockIssuance | 0.00 | -200.00M | 0.00 | -6.36B |
| CommonStockPayments | 0.00 | -200.00M | 0.00 | -6.36B |
| NetIssuancePaymentsOfDebt | -5.00B | -3.60B | 26.32B | 6.92B |
| NetLongTermDebtIssuance | -5.00B | -3.60B | 26.32B | 6.92B |
| LongTermDebtPayments | -5.00B | -3.60B | -1.45B | 0.00 |
| LongTermDebtIssuance | 0.00 | 0.00 | 27.78B | 6.92B |
| InvestingCashFlow | -1.94B | -1.05B | -26.20B | -6.04B |
| CashFlowFromContinuingInvestingActivities | -1.94B | -1.05B | -26.20B | -6.04B |
| NetOtherInvestingChanges | -32.00M | 50.00M | 224.00M | 100.00M |
| NetInvestmentPurchaseAndSale | 0.00 | 0.00 | 1.67B | -1.37B |
| SaleOfInvestment | 0.00 | 0.00 | 1.67B | 1.22B |
| PurchaseOfInvestment | 0.00 | -1.00M | -2.59B | -8.90B |
| NetBusinessPurchaseAndSale | -53.00M | 0.00 | -26.99B | -3.84B |
| SaleOfBusiness | 130.00M | 0.00 | ||
| PurchaseOfBusiness | -53.00M | 0.00 | -26.99B | -3.84B |
| NetPPEPurchaseAndSale | -1.86B | -1.10B | -1.11B | -936.00M |
| PurchaseOfPPE | -1.86B | -1.10B | -1.11B | -936.00M |
| OperatingCashFlow | 9.96B | 11.49B | 8.47B | 9.72B |
| CashFlowFromContinuingOperatingActivities | 9.96B | 11.49B | 8.47B | 9.72B |
| ChangeInWorkingCapital | -1.98B | 2.37B | -484.00M | -733.00M |
| ChangeInOtherWorkingCapital | 499.00M | 92.00M | 953.00M | |
| ChangeInOtherCurrentLiabilities | -156.00M | -51.00M | -222.00M | -182.00M |
| ChangeInOtherCurrentAssets | -1.27B | -652.00M | -564.00M | 258.00M |
| ChangeInPayablesAndAccruedExpense | 736.00M | 3.00M | -127.00M | 679.00M |
| ChangeInAccruedExpense | 2.06B | 1.19B | 935.00M | 943.00M |
| ChangeInPayable | -1.33B | -1.19B | -1.06B | -264.00M |
| ChangeInAccountPayable | 428.00M | 312.00M | -402.00M | 154.00M |
| ChangeInTaxPayable | -1.76B | -1.50B | -660.00M | -418.00M |
| ChangeInIncomeTaxPayable | -1.76B | -1.50B | -660.00M | -418.00M |
| ChangeInInventory | 886.00M | 2.53B | 491.00M | -742.00M |
| ChangeInReceivables | -2.68B | 441.00M | -1.01B | -746.00M |
| ChangesInAccountReceivables | -2.68B | 441.00M | -1.01B | -746.00M |
| OtherNonCashItems | 149.00M | -177.00M | -277.00M | -303.00M |
| StockBasedCompensation | 494.00M | 530.00M | 431.00M | 401.00M |
| AssetImpairmentCharge | 1.20B | 159.00M | 851.00M | |
| DeferredTax | -721.00M | -1.23B | -1.27B | -1.20B |
| DeferredIncomeTax | -721.00M | -1.23B | -1.27B | -1.20B |
| DepreciationAmortizationDepletion | 5.17B | 5.59B | 4.07B | 3.42B |
| DepreciationAndAmortization | 5.17B | 5.59B | 4.07B | 3.42B |
| Depreciation | 5.17B | 5.59B | 4.07B | 3.42B |
| OperatingGainsLosses | -2.06B | 159.00M | -1.56B | 1.58B |
| EarningsLossesFromEquityInvestments | -10.00M | 11.00M | 891.00M | 33.00M |
| GainLossOnInvestmentSecurities | -2.06B | 159.00M | -1.56B | 127.00M |
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | 567.00M | 0.00 |
| NetIncomeFromContinuingOperations | 7.71B | 4.09B | 6.72B | 6.55B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AMGN
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|